Sun on defensive after Indian parliamentary report claims letrozole irregularities
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries says that it has conducted postmarketing surveillance studies for the breast cancer drug, letrozole, in India, even as a report by a parliamentary standing committee on health and family welfare in the country demanded action against the firm for alleged deficiencies in trial practice and follow up studies.